Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05220501 · ClinicalTrials.gov registry record · NA

Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

A NA study, sponsored by Sunnybrook Health Sciences Centre.

Completed
Registry status
NA
Development phase
804
Enrollment target

NCT05220501: Completed NA study, sponsored by Sunnybrook Health Sciences Centre.

NCT05220501 is a NA study that has completed, run by Sunnybrook Health Sciences Centre. The registered enrollment target is 804 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05220501, a NA study, has completed, sponsored by Sunnybrook Health Sciences Centre.

COMPLETED
Registry status
NA
Development phase
804 participants
Enrollment target

Study Summary

OPTIMUM is a study designed to compare the ability of ultra-high resolution transrectal micro-ultrasound (microUS) and multiparametric MRI (mpMRI)/US fusion to guide prostate biopsy.

Primary Outcome

As per protocol, the microultrasonography group for the primary outcome is defined as the microultrasonography-guided biopsy group and the blinded portion (microultrasound targets are identified prior to the unblinding of the MRI targets identified in the microultrasonography/mpMRI group). Difference in the detection rate of clinically significant prostate cancer (defined as equal to Gleason Grade Group 2 or higher) found using microultrasonography-guided biopsy, including targeted and systemat

Interventions

  • DIAGNOSTIC_TEST Microultrasonography Targeted Biopsy
  • DIAGNOSTIC_TEST MRI Targeted Biopsy

Trial Details

FieldValue
Enrollment Target 804 participants
Start Date 2021-12-15
Est. Completion 2024-09-06
Phase NA

What the finished NCT05220501 record still lists

NCT05220501 is an interventional study that assigns participants to a tested intervention. The registered 804 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).

The record links to 0 conditions, and to 2 interventions - of which Microultrasonography Targeted Biopsy is the first listed.

NCT05220501 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05220501 about?

NCT05220501 is a clinical study titled "Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI". OPTIMUM is a study designed to compare the ability of ultra-high resolution transrectal micro-ultrasound (microUS) and multiparametric MRI (mpMRI)/US fusion to guide prostate biopsy.

What is the current status of trial NCT05220501?

This trial is currently completed. It is a NA study. The enrollment target is 804 participants. The study started on 2021-12-15. Estimated completion is 2024-09-06.

What interventions are being tested in trial NCT05220501?

The interventions under investigation include: Microultrasonography Targeted Biopsy (DIAGNOSTIC_TEST), MRI Targeted Biopsy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05220501?

This trial is sponsored by Sunnybrook Health Sciences Centre, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05220501's enrollment target sits among peer trials

804 134th of 2000 higher than 1,867 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04423211 · 804 participants · Phase 3

    Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • NCT06522022 · 804 participants · NA

    PTSD Screening in Pregnant Black Women

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06065098 · 806 participants · NA

    Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05220501, the US trial registry maintained by the National Library of Medicine. NCT05220501 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.